Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06610682 · ClinicalTrials.gov registry record · Early Phase 1
Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib
A Early Phase 1 study of BRAF V600E Mutation, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06610682 is a Early Phase 1 study of BRAF V600E Mutation that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06610682, a Early Phase 1 study of BRAF V600E Mutation, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluating the sensitivity and feasibility of using ctDNA assays optimized for detecting very low ctDNA counts from cerebrospinal fluid (CSF) and plasma. The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as Cycle1 Day1 (C1D1) pre-treatment) and over time in response to treatment with plixorafenib co-administered with cobicistat in BRAF-V600E mutant glioma refractory to prior therapies.
Conditions Studied
Interventions
- DRUG Plixorafenib
- DRUG Cobicistat 150 MG [Tybost]
Study Locations (1)
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2027-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06610682
The ClinicalTrials.gov registry entry for NCT06610682 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with BRAF V600E Mutation appearing as the primary indexed condition, and to 2 interventions - of which Plixorafenib is the first listed.
NCT06610682 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06610682 about?
NCT06610682 is a clinical study titled "Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib". Evaluating the sensitivity and feasibility of using ctDNA assays optimized for detecting very low ctDNA counts from cerebrospinal fluid (CSF) and plasma. The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as Cycle1 Day1 (C1D1) pre-treatment) and over ti...
What is the current status of trial NCT06610682?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2025-04-07. Estimated completion is 2027-06-30.
What conditions does trial NCT06610682 study?
This clinical trial studies the following conditions: BRAF V600E Mutation.
What interventions are being tested in trial NCT06610682?
The interventions under investigation include: Plixorafenib (DRUG), Cobicistat 150 MG [Tybost] (DRUG).
Who is sponsoring clinical trial NCT06610682?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06610682 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.